MERGER ALERT – CMTA and ONCE: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies

NEW YORK, March 26, 2019 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:

Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies.

Clementia Pharmaceuticals Inc. CMTA

Merger Announcement: February 25, 2019

Transaction Details: Under the terms of the transaction, Ipsen will purchase Clementia for US$25 per share. Clementia's largest shareholder, OrbiMed Private Investments IV, LP, has already agreed to tender its shares.

To learn more about the CMTA investigation and your rights, go to: https://www.zlk.com/mna/clementia-pharmaceuticals-inc.

Spark Therapeutics, Inc. ONCE

Merger Announcement: February 25, 2019

Transaction Details: Under the terms of the transaction, Roche will purchase Spark for US$114.50 per share.

To learn more about the ONCE investigation and your rights, go to: https://www.zlk.com/mna/spark-therapeutics-inc.

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

jlevi@levikorsinsky.com

55 Broadway, 10th Floor

New York, NY 10006

Tel: (212) 363-7500

Toll Free: (877) 363-5972

Fax: (212) 363-7171

www.zlk.com

250x148_zlk.jpg

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsLegalPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!